KALMAR CORPORATION, STOCK EXCHANGE RELEASE, 13 FEBRUARY 2026, AT 9.00 AM (EET)  Kalmar’s financial statements review January–December 2025: Continued successful performance in 2025 with record order intake and solid sales growth in the fourth quarterOrders received increased to a record of EUR 511 (486) million boosted by a few, sizeable equipment orders in the quarter Strong sales growth by 11 percent to EUR 487 (440) million Demand remained overall stable despite market uncertainty and trade tensions Comparable operating profit improved to EUR 60.5 (53.1) million, and was 12.4 (12.1) percentage of sales Approximately EUR 34 million of annualised gross efficiency improvements have been secured with the Driving Excellence initiative Operating cash flow increased 76 percent to MEUR 112.8 (64.2), positively impacted by inventory...

HBC recorded total operating revenues of NOK 72.2 million in the fourth quarter of 2025, compared to NOK 64.9 million in the same period last year. Net operating revenues were NOK 71.1 million, up from NOK 64.9 million in Q4 2024. Full year 2025, total operating revenues amounted to NOK 256.3 million (265.5). Total operating revenue in 2024 included NOK 8.1 million of gain on sale of assets. EBITDA for the quarter was negative NOK 26.5 million, compared to negative NOK 26.1 million in Q4 2024. For full year 2025, EBITDA was negative NOK 72.9 million (-65.3). The Operational EBITDA* amounted to negative NOK 19.7 million (negative NOK 15.6 million in Q4 2024), excluding non-recurring and strategic development costs such as clinical trials and R&D expenses, and Berkåk project costs. For full year 2025, Operational EBITDA* was negative...

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed here. Christopher Cargill, President and CEO of Nxera Pharma, commented: “2025 was a year of disciplined execution and strategic progress for Nxera, as we continued to build a more focused, resilient and scalable biopharmaceutical business with a growing commercial footprint in Japan and a maturing pipeline. “In doing so, we further strengthened our commercial foundations in Japan and the broader APAC region, with PIVLAZ® for the prevention of cerebral vasospasm after aneurysmal subarachnoid haemorrhage firmly established as the standard of care in Japan. We...

Media relations:Victoire GruxTel.: +33 6 04 52 16 55victoire.grux@capgemini.com Investor relations:Vincent BiraudTel.: +33 1 47 54 50 87vincent.biraud@capgemini.com Full-year 2025 resultsRevenues of €22,465 million in 2025, up +1.7% Revenue growth at constant exchange rates* of +3.4% for the full year, and +10.6% in Q4 Bookings up +3.9% at constant exchange rates to €24.4 billion with a 1.08 book-to-bill Stable operating margin*, at 13.3% of revenues Net profit, Group share, of €1,601 million Basic earnings per share of €9.46, down -3.7% and normalized earnings per share of €12.95, up +5.8% Organic free cash flow* stable at €1.95 billion Proposed dividend of €3.40 per shareParis, February 13, 2026 – The Board of Directors of Capgemini SE, chaired by Paul Hermelin, convened on February 12, 2026 in Paris to review and adopt the accounts1...

PERTH, Australia, Feb. 12, 2026 (GLOBE NEWSWIRE) — Alkane Resources Limited (“Alkane” or the “Company”) (ASX: ALK, OTC: ALKRY, TSX: ALK) is pleased to announce financial results for the six months ended 31 December 2025 (the “half” or “HY 2026”). The Company’s condensed and consolidated interim financial result for the half, together with the Appendix 4D and Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under Alkane’s profile on www.sedarplus.ca, on the Australian Securities Exchange (“ASX”) and on Alkane’s website at www.alkres.com. All currency references in this press release are in Australian dollars except as otherwise indicated. First Half 2026 Highlights: 1,2Record Revenues: Gold equivalent sales for the half year of 74,094 ounces generated revenues of $404 million at...

 US$82 Million in Pending Proposals Across Multiple Infectious Disease Programs US$40 Million NIAID Funding Award Supports VXV-01 Development Through Phase 1 LIKMEZ® (ATI-1501) Commercial Momentum with Increased U.S. Market Adoption HALIFAX, Nova Scotia, Feb. 12, 2026 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the third quarter of its fiscal year 2026, which ended on December 31, 2025. All figures are in Canadian dollars unless otherwise stated. “During the past quarter, we made important progress in advancing multiple U.S. federal funding proposals that, if awarded, could meaningfully support our key pipeline...

ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025. “As we close out the fourth quarter, CRISPR Therapeutics continues to make steady progress across a broad and increasingly mature pipeline,” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “We made meaningful advances across multiple clinical and preclinical programs, including encouraging data from zugo-cel in autoimmune disease and oncology, continued global uptake of CASGEVY, and important developments across our in vivo liver editing portfolio, and momentum in our siRNA collaboration with Sirius Therapeutics. At the same time, we continue to strengthen our platform capabilities to support long-term...

Selected HighlightsFourth quarter Operating EBITDA* was negative $20.1 million (net loss of $308.7 million) compared to negative $28.1 million (net loss of $80.8 million) in the third quarter of 2025 Full year 2025 Operating EBITDA was negative $22.0 million (net loss of $497.9 million) compared to positive $243.7 million (net loss of $85.1 million) in 2024 Included in net loss for the fourth quarter are total non-cash impairments of $238.7 million, primarily on long-lived assets at our Peace River mill due to the continued down-cycle environment in hardwood pulp markets and on pulp inventory due to low prices and high fiber costs “One Goal One Hundred” program remains on track, with approximately $30.0 million in cost savings and operational efficiencies in 2025 Despite the challenging environment, cash flow from operations...

ARCHBOLD, Ohio, Feb. 12, 2026 (GLOBE NEWSWIRE) — Farmers & Merchants Bancorp, Inc. (Nasdaq: FMAO) today reported financial results for the 2025 fourth quarter and twelve months ended December 31, 2025, on a consolidated basis. 2025 Fourth-Quarter Financial and Operating Highlights(at December 31, 2025, and on a year-over-year basis unless noted)91 consecutive quarters of profitability Net income increased 16.8% to a quarterly record of $9.8 million, or $0.71 per basic and diluted share Net charge-offs to average loans of 0.01% Tier 1 leverage ratio was 8.81% Cost of interest-bearing liabilities improved to 2.69%, from 3.01% Net interest margin increased by 62 basis points year-over-year to 3.46% Efficiency ratio improved to 58.38%, compared to 59.82% Fourth quarter dividend per share increased 4.0% to $0.92 annualized, reflecting...

Reported Positive Net Income Set Records for Revenue and Adjusted EBITDA BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced its fourth quarter and fiscal year 2025 financial results. The Company also posted a letter to shareholders and an earnings presentation on the Investor Relations section of its website at investors.draftkings.com. Fourth Quarter 2025 HighlightsFor the three months ended December 31, 2025, DraftKings reported revenue of $1,989 million, an increase of $596 million, or 43%, compared to $1,393 million during the same period in 2024. The increase in the Company’s fourth quarter 2025 revenue was driven primarily by continued healthy customer engagement, efficient acquisition of new customers, and higher Sportsbook net revenue margin. “We closed...